200,000+ products from a single source!
sales@angenechem.com
3543-75-7 | 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid hydrochloride
CAS No: 3543-75-7 Catalog No: AG0039BQ MDL No:MFCD16879055
Product Description
Catalog Number:
AG0039BQ
Chemical Name:
4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid hydrochloride
CAS Number:
3543-75-7
Molecular Formula:
C16H22Cl3N3O2
Molecular Weight:
394.7238
MDL Number:
MFCD16879055
IUPAC Name:
4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
InChI:
InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
InChI Key:
ZHSKUOZOLHMKEA-UHFFFAOYSA-N
SMILES:
ClCCN(c1ccc2c(c1)nc(n2C)CCCC(=O)O)CCCl.Cl
UNII:
981Y8SX18M
NSC Number:
138783
Properties
Complexity:
380
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
393.078g/mol
Formal Charge:
0
Heavy Atom Count:
24
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
394.721g/mol
Monoisotopic Mass:
393.078g/mol
Rotatable Bond Count:
9
Topological Polar Surface Area:
58.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. | The New England journal of medicine 20180322 |
| Mantle Cell Lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20160410 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. | Cancer chemotherapy and pharmacology 20150101 |
| ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. | Biochemical pharmacology 20130401 |
| Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. | Leukemia & lymphoma 20121101 |
| Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. | Expert opinion on drug metabolism & toxicology 20121101 |
| Novel agents in Hodgkin lymphoma. | Current oncology reports 20121001 |
| Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. | British journal of haematology 20121001 |
| Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma. | Drugs 20121001 |
| Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120915 |
| Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. | The Cochrane database of systematic reviews 20120912 |
| Small molecule drugs - optimizing DNA damaging agent-based therapeutics. | Current opinion in pharmacology 20120801 |
| Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. | Journal of cancer research and clinical oncology 20120801 |
| Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. | Drug metabolism and disposition: the biological fate of chemicals 20120701 |
| Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). | British journal of haematology 20120701 |
| Optimizing premedications in the prevention of bendamustine infusion-related reactions. | Cancer control : journal of the Moffitt Cancer Center 20120701 |
| Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation. | Hematological oncology 20120601 |
| Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. | Clinical lymphoma, myeloma & leukemia 20120601 |
| [Impending liver failure after chemoimmunotherapy-induced reactivation of hepatitis B - successful treatment with entecavir]. | Deutsche medizinische Wochenschrift (1946) 20120601 |
| Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. | Blood 20120517 |
| Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. | Journal of neuro-oncology 20120501 |
| Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415 |
| Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. | Leukemia & lymphoma 20120401 |
| Pneumocystis jiroveci Pneumonia in an Atypical Host. | Clinical breast cancer 20120401 |
| Cutaneous granulomatous vasculitis associated with chronic lymphocytic leukemia: case report and review of literature of a rare entity. | Dermatology online journal 20120315 |
| Bendamustine: inadequate or outdated data. | Prescrire international 20120301 |
| Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. | The Journal of antimicrobial chemotherapy 20120201 |
| The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. | Blood cells, molecules & diseases 20120115 |
| Uncommon recurrence of follicular lymphoma. | European journal of haematology 20120101 |
| Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101 |
| Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. | British journal of haematology 20111201 |
| BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. | Blood 20110922 |
| Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110910 |
| Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110901 |
| Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| [Development of novel agents for multiple myeloma; now and the future]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801 |
| Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. | British journal of cancer 20110712 |
| New agents in follicular lymphoma. | Best practice & research. Clinical haematology 20110601 |
| Bivalent bendamustine and melphalan derivatives as anticancer agents. | European journal of medicinal chemistry 20110501 |
| Changing therapeutic landscape--the last decade. | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20110401 |
| Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. | Seminars in hematology 20110401 |
| Bendamustine's emerging role in the management of lymphoid malignancies. | Seminars in hematology 20110401 |
| Conclusion and future directions. | Seminars in hematology 20110401 |
| The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. | Blood 20110310 |
| Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. | Cancer science 20110201 |
| Chronic lymphocytic leukemia: something old, something new and something borrowed.. | Medicine and health, Rhode Island 20110101 |
| Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. | Hematology/oncology and stem cell therapy 20110101 |
| B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells. | Leukemia 20101101 |
| Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents. | Bioconjugate chemistry 20101020 |
| Current immunochemotherapy strategies in follicular lymphoma. | Advances in therapy 20101001 |
| Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. | Drugs 20100910 |
| Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. | Journal of the National Comprehensive Cancer Network : JNCCN 20100901 |
| Severe cutaneous interface drug eruption associated with bendamustine. | Dermatology online journal 20100715 |
| Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? | Current hematologic malignancy reports 20100701 |
| Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. | Journal of the National Cancer Institute 20100616 |
| Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. | Clinical advances in hematology & oncology : H&O 20100501 |
| (18)F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging. | Bioorganic & medicinal chemistry 20100401 |
| Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. | Clinical advances in hematology & oncology : H&O 20100401 |
| Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. | Clinical advances in hematology & oncology : H&O 20100401 |
| Changing paradigms in the treatment of chronic lymphocytic leukemia. | Leukemia 20100301 |
| Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana. | Clinical advances in hematology & oncology : H&O 20100201 |
| Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. | Leukemia & lymphoma 20100101 |
| Bendamustine in patients with relapsed or refractory multiple myeloma. | European journal of medical research 20100101 |
| Bendamustine-associated hemolytic anemia. | The Annals of pharmacotherapy 20091101 |
| Bendamustine: a new treatment option for chronic lymphocytic leukemia. | Pharmacotherapy 20091101 |
| Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents. | Current hematologic malignancy reports 20091001 |
| Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910 |
| Bendamustine in chronic lymphocytic leukemia: the future is combination therapy. | Leukemia & lymphoma 20090901 |
| Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. | Leukemia & lymphoma 20090901 |
| Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. | Blood 20090820 |
| Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. | Current opinion in hematology 20090701 |
| Bendamustine therapy in chronic lymphocytic leukemia. | Expert opinion on pharmacotherapy 20090701 |
| Medicinal chemistry strategies in follow-on drug discovery. | Drug discovery today 20090501 |
| Bendamustine: rebirth of an old drug. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320 |
| Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. | Journal of cancer research and clinical oncology 20090201 |
| Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. | Drug metabolism and disposition: the biological fate of chemicals 20090201 |
| Bendamustine: a new look at an old drug. | Cancer 20090201 |
| Bendamustine in the treatment of chronic lymphocytic leukemia. | Expert review of anticancer therapy 20090201 |
| State-of-the-art treatment of chronic lymphocytic leukemia. | Hematology. American Society of Hematology. Education Program 20090101 |
| Novel therapies for relapsed myeloma. | Hematology. American Society of Hematology. Education Program 20090101 |
| Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. | Clinical therapeutics 20090101 |
| HPLC study on the stability of bendamustine hydrochloride immobilized onto polyphosphoesters. | Journal of pharmaceutical and biomedical analysis 20081201 |
| Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081101 |
| Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. | British journal of haematology 20081001 |
| [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001 |
| Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080920 |
| Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. | Clinical advances in hematology & oncology : H&O 20080901 |
| Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. | Clinical lymphoma & myeloma 20080801 |
| Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. | Seminars in hematology 20080701 |
| Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. | The American journal of the medical sciences 20080501 |
| Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. | Journal of cancer research and clinical oncology 20080201 |
| Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080101 |
| American Society of Hematology annual meeting. | The Lancet. Oncology 20080101 |
| New drugs: Ciclesonide, certolizumab pegol, and bendamustine hydrochloride. | Journal of the American Pharmacists Association : JAPhA 20080101 |
| What is the correct philosophy for the treatment of multiple myeloma? | Leukemia & lymphoma 20071201 |
| Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. | Leukemia & lymphoma 20071201 |
| Metabolic profile of [(14)C]bendamustine in rat urine and bile: preliminary structural identification of metabolites. | Drug metabolism and disposition: the biological fate of chemicals 20071001 |
| First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. | European journal of haematology 20070901 |
| Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. | Anti-cancer drugs 20070901 |
| Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). | Cancer 20070815 |
| Bendamustine for advanced sarcoma. | The Lancet. Oncology 20070801 |
| Combination treatment approaches and novel therapies for lymphoma. | Clinical advances in hematology & oncology : H&O 20070801 |
| High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). | Leukemia & lymphoma 20070701 |
| A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. | British journal of cancer 20070604 |
| Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML. | Leukemia & lymphoma 20070601 |
| Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. | Cancer chemotherapy and pharmacology 20070501 |
| [Recent therapeutic strategy for follicular lymphoma]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070410 |
| Medical treatment of uveal melanoma. | Tumori 20070101 |
| Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). | Journal of cancer research and clinical oncology 20060401 |
| Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). | Journal of cancer research and clinical oncology 20060201 |
| Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. | European journal of haematology 20051201 |
| Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. | Anti-cancer drugs 20050901 |
| Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. | Drug metabolism and disposition: the biological fate of chemicals 20050701 |
| A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. | Melanoma research 20041201 |
| Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. | Leukemia & lymphoma 20041201 |
| Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). | Leukemia & lymphoma 20040901 |
| Advances in chemotherapy for chronic lymphocytic leukemia. | Seminars in hematology 20040701 |
| Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. | Leukemia & lymphoma 20040701 |
| Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. | Leukemia & lymphoma 20040501 |
| Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. | Biochemical pharmacology 20030901 |
| [Current concepts in chronic lymphocytic leukemia. Better chances for young patients]. | MMW Fortschritte der Medizin 20030710 |
| Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. | Journal of cancer research and clinical oncology 20030501 |
| High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. | Journal of cancer research and clinical oncology 20021101 |
| In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. | Leukemia 20021001 |
| Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. | Seminars in oncology 20020801 |
| Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. | Seminars in oncology 20020801 |
| Bendamustine in the treatment of multiple myeloma: results and future perspectives. | Seminars in oncology 20020801 |
| Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. | Seminars in oncology 20020801 |
| Hematologic malignancies: new developments and future treatments. | Seminars in oncology 20020801 |
| Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. | Journal of cancer research and clinical oncology 20020501 |
| Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. | Leukemia & lymphoma 20020201 |
| Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. | Haematologica 20020101 |
| In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. | Haematologica 20010501 |
| Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. | Annals of hematology 20010301 |
| Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. | Journal of cancer research and clinical oncology 20010101 |
| Bendamustine. | Drugs 20010101 |
| Toxicity of the alkylating agent bendamustin. | Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement 19850101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.